Patents Assigned to Institut Curie
  • Publication number: 20200291466
    Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.
    Type: Application
    Filed: July 11, 2018
    Publication date: September 17, 2020
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Universite de Versailles Saint-Quentin-en-Yvelines
    Inventors: Charlotte PROUDHON, Amélie KASPEREK, Amanda BORTOLINI SILVEIRA, François-Clément BIDARD, Marc-Henri STERN
  • Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Patent number: 10767151
    Abstract: A device for cell culture, in particular of neuronal cells, including: a substrate defining a first microfluidic chamber to be seeded with a first cell culture, and at least a second microfluidic chamber, a fluidic interconnection system connecting the first and second chambers and enabling cellular extensions, in particular axons, to extend from one chamber to the other, wherein the interconnection system of the device is made so as to promote the progression of at least one first type of cellular extension, the first and second types of extension being different either due to the microfluidic chamber from which they originate, or due to the type of cell of which they constitute an extension.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: September 8, 2020
    Assignees: CNRS-DAE, INSTITUT CURIE, SORBONNE UNIVERSITE
    Inventors: Jean-Louis Viovy, Jean-Michel Peyrin, Bernard Brugg, Laure Saias, Paul Gougis, Maeva Vignes
  • Patent number: 10752668
    Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: August 25, 2020
    Assignees: Theravectys, Institut Curie, Centre National de la Recherche Scientifique, Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sophie Agaugue, Lorenzo Tibaldi, Klervi Even-Desrumaux, Dmitry Trubetskoy, Franck Perez, Sebastian Amigorena, Cécile Bauche
  • Publication number: 20200247046
    Abstract: A microfluidic print head of a printer has a distal face, an injection channel, a suction channel, a groove, and a light source or an optical waveguide. The injection channel is configured to inject an ink onto a substrate and leads onto the distal face by an injection opening The suction channel is configured to suck up the ink and leads onto the distal face by a suction opening. The groove is defined on the distal face and into which the suction opening leads.
    Type: Application
    Filed: August 3, 2018
    Publication date: August 6, 2020
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, SORBONNE UNIVERSITE
    Inventors: Laurent Malaquin, Jean Louis Viovy, Sandrine Souleille, Xavier Dollat, Victor Fournie
  • Publication number: 20200239444
    Abstract: A compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 30, 2020
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre ROUX, Florence MAHUTEAU, Romain NAJMAN, Gilles GADEA, Jamal TAZI, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC
  • Patent number: 10717724
    Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: July 21, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
  • Patent number: 10718770
    Abstract: The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 21, 2020
    Assignees: ABIV AX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
  • Patent number: 10683284
    Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: June 16, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Julien Santo
  • Publication number: 20200171499
    Abstract: A microfluidic device for performing physical, chemical or biological treatment to at least one packet without contamination.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 4, 2020
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Louis VIOVY, Max CHABERT, Kevin DORFMAN
  • Publication number: 20200172525
    Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 4, 2020
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN, Didier SCHERRER, Julien SANTO
  • Patent number: 10661274
    Abstract: Disclosed is a fluidic device including at least: a) a solid matrix; b) a textile component, embedded in the matrix and mechanically cohesive with the matrix; c) at least one channel embedded in the matrix and entangled with the textile component, the channel being at least partly open. A method for making a fluidic device includes providing a textile component including support fibers and at least a movable fiber entangled with the textile, embedding at least part of the textile and part of the movable fiber, in a matrix precursor material, applying a treatment in order to obtain a solid matrix.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: May 26, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE PIERRE ET MARIE CURIE
    Inventors: Jean-Louis Viovy, Bastien Venzac, Laurent Malaquin, Stephanie Descroix
  • Patent number: 10661278
    Abstract: A microfluidic device for performing physical, chemical or biological treatment to at least one packet without contamination.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: May 26, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Louis Viovy, Max Chabert, Kevin Dorfman
  • Patent number: 10654813
    Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 19, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
  • Publication number: 20200124611
    Abstract: Fluorescent labeling of proteins. In particular, membrane-impermeant fluorogenic chromophores being capable of binding reversibly a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labeling biological molecules of interest, preferably proteins of interest. Especially, 4-hydroxybenzylidene-rhodanine (HBR) analogs of formula (II) as membrane-impermeant fluorogenic chromophores.
    Type: Application
    Filed: May 18, 2018
    Publication date: April 23, 2020
    Applicants: PARIS SCIENCES ET LETTRES - QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, SORBONNE UNIVERSITE
    Inventors: Arnaud GAUTIER, Ludovic JULLIEN, Chenge LI, Franck PEREZ
  • Patent number: 10603265
    Abstract: The present invention provides new peptides useful as skin whitening agents and their uses in cosmetic or therapeutic applications.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 31, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Graca Raposo, Cecile Campagne, Cedric Delevoye
  • Patent number: 10576103
    Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: March 3, 2020
    Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALS (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS
    Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni
  • Patent number: 10563197
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: February 18, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • Patent number: 10538485
    Abstract: The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 21, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Romain Najman, Florence Mahuteau, Pierre Roux
  • Publication number: 20190382347
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Application
    Filed: August 29, 2019
    Publication date: December 19, 2019
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN